Balanced Solutions Voluntarily Recalls Sterile Products

News
Article

Third compounding pharmacy recalls products due to FDA inspection.

Balanced Solutions Compounding Pharmacy, a division of Axium Healthcare Pharmacy, of Lake Mary, Florida, has announced a voluntarily recall of all lots of its sterile non-expired drug products due to a lack of sterility assurance and concerns with product quality controls, according to FDA. This is the third compounding pharmacy to issue a recall this month. NuVision Pharmacy and ApothéCure announced recalls due to sterility concerns on April 15.

FDA states that during an inspection of Balanced Solutions’ facility investigators observed poor practices and conditions, which may have exposed the company’s sterile products to microbial contamination. Further analysis confirmed FDA concerns. FDA identified gram-negative bacteria, a type of contaminant, in a sample chromium chloride injection from Balanced Solutions. According to FDA, Gram-negative bacteria can cause disease and many types of infection, but the Sphingobacterium thalpophilum bacteria found in the solution does not usually cause infection in humans.

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.